{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Food and Drug Admin settles case with Amarin, granting company leeway to promote drug Vascepa for uses that have not yet been approved; deal could have wider effect on how some drugs are marketed.  ", "type_of_material": "News", "word_count": "720", "lead_paragraph": "The Food and Drug Administration will now allow Amarin to sell Vascepa, an omega-3 fatty acid, for both high and low triglyceride levels.", "pub_date": "2016-03-09T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Deal Allows Amarin to Promote Drug for Off-Label Use", "print_headline": "Deal Allows Promotion of Off-Label Use of Drug"}, "snippet": "The Food and Drug Administration will now allow Amarin to sell Vascepa, an omega-3 fatty acid, for both high and low triglyceride levels.", "multimedia": [{"height": 126, "url": "images/2016/03/08/business/0309vascepa/0309vascepa-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/08/business/0309vascepa/0309vascepa-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 776, "url": "images/2016/03/08/business/0309vascepa/0309vascepa-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "776", "xlarge": "images/2016/03/08/business/0309vascepa/0309vascepa-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/08/business/0309vascepa/0309vascepa-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/08/business/0309vascepa/0309vascepa-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/09/business/fda-deal-allows-amarin-to-promote-drug-for-off-label-use.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Advertising and Marketing", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Amarin Corp PLC", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Freedom of Speech and Expression", "name": "subject"}], "blog": [], "_id": "56df7ee738f0d836dc035a08", "source": "The New York Times"}